SCHEMBL6263109

SCHEMBL6263109

CC(C)=CCC/C(C)=C/CS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.51
CTSK P43235 1/20 0.46
PTGS1 P23219 3/20 0.43
KMT2A Q03164 2/20 0.43
PGR P06401 1/20 0.43
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
MAPT P10636 1/20 0.43
PDE4A P27815 1/20 0.43
MAPK1 P28482 1/20 0.43
DRD3 P35462 1/20 0.43
SNCA P37840 1/20 0.43
PDE3A Q14432 1/20 0.43
ALOX5 P09917 1/20 0.43
PTPN1 P18031 1/20 0.42
BACE1 P56817 1/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263113 1.00 TRPV1 (0.51) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL31678748 1.00 TRPV1 (0.51) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL9419767 0.98 TRPV1 (0.50) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL10405653 0.98 TRPV1 (0.50) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL9770419 0.98 TRPV1 (0.50) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL11484335 0.98 TRPV1 (0.50) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL10405654 0.98 TRPV1 (0.50) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL10921446 0.90 CTSK (0.45) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL10921443 0.90 CTSK (0.45) TRPV1CTSKPTGS1KMT2APGR
SCHEMBL11484782 0.87 CTSK (0.43) TRPV1CTSKPTGS1KMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270152-A1 PROCESS FOR PREPARING beta-FARNESENES AND 2-(3-ALKENYL)-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-08-28 US disclosed
CN-114874072-A Preparation method of geranylgeraniol 广西民族师范学院 2022-08-09 CN disclosed
EP-1072589-B1 Process for producing lycopene and intermediate thereof SUMITOMO CHEMICAL CO (JP) 2005-11-09 EP disclosed
CN-1158253-C Process for preparing prolycopene and its intermediate ס�ѻ�ѧ��ҵ��ʽ���� 2004-07-21 CN disclosed
EP-0983998-B1 Tetraene derivative and process for producing the same SUMITOMO CHEMICAL CO (JP) 2003-03-26 EP disclosed
US-6331652-B1 Process for producing lycopene and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-18 US disclosed
EP-0881204-B1 Polyene alcohol derivative and process for producing the same SUMITOMO CHEMICAL CO (JP) 2001-11-14 EP disclosed
CN-1286247-A Process for preparing prolycopene and its intermediate SUMITOMO CHEMICAL CO (JP) 2001-03-07 CN disclosed
EP-1072589-A2 Process for producing lycopene and intermediate thereof Sumitomo Chemical Company, Limited (JP) 2001-01-31 EP disclosed
US-6087541-A Polyene alcohol derivative and process for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-07-11 US disclosed
EP-0282915-B1 PROCESS FOR PREPARING SULFONE COMPOUNDS KURARAY CO., LTD. (JP) 1991-04-17 EP disclosed
EP-0421419-A2 Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders Bristol-Myers Squibb Company (US) 1991-04-10 EP disclosed
US-4886916-A REACTING (GERANYL, NERYL, OR LINALYL) CHLORIDE WITH ALKALI METAL PHENYL SULFINATE KURARAY COMPANY, LTD. (JP) 1989-12-12 US disclosed
EP-0282915-A1 Process for preparing sulfone compounds KURARAY CO., LTD. (JP) 1988-09-21 EP disclosed
EP-0243849-A2 Process for the production of polyprenoid type compounds YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) 1987-11-04 EP disclosed
US-4613571-A OXIDATION BY NOCARDIA ESAI CO., LTD. (JP) 1986-09-23 US disclosed
EP-0067938-B1 POLYPRENYL SULFONE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USES Eisai Co., Ltd. (JP) 1984-12-27 EP disclosed
US-4449002-A CHEMICAL INTERMEDIATES FOR ANTIULCER AND HYPOTENSIVE AGENTS SUCH AS COENZYME Q10 EISAI CO., LTD. (JP) 1984-05-15 US disclosed
EP-0067938-A1 Polyprenyl sulfone derivatives, process for producing them and their uses Eisai Co., Ltd. (JP) 1982-12-29 EP disclosed
US-4199531-A Intermediates for the production of quinones TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1980-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270152-A1 PROCESS FOR PREPARING beta-FARNESENES AND 2-(3-ALKENYL)-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF GGPS1, HSD3B1, HSD3B2 TRPV1 2338/4885CTSK 3747/4885PTGS1 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.